日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment

早期调整贝伐单抗的剂量和给药时间可能会影响阿特珠单抗联合贝伐单抗治疗晚期肝细胞癌的疗效。

Rossari, F; Lavacchi, D; Alimenti, E; Soldà, C; Salani, F; Esposito, L; Foti, S; Camera, S; Persano, M; Lo Prinzi, F; Vitiello, F; Pellegrini, E; Bruccoleri, M; Rizzato, M D; Caccese, M; Rapposelli, I G; Guidolin, A; De Rosa, A; Antonuzzo, L; Masi, G; Iavarone, M A; Lonardi, S; Rimini, M; Casadei-Gardini, A

Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma

通过递归分割分析法鉴定晚期肝细胞癌中乐伐替尼预后指数

Rapposelli, I G; Shimose, S; Kumada, T; Okamura, S; Hiraoka, A; Di Costanzo, G G; Marra, F; Tamburini, E; Forgione, A; Foschi, F G; Silletta, M; Lonardi, S; Masi, G; Scartozzi, M; Nakano, M; Shibata, H; Kawata, K; Pellino, A; Vivaldi, C; Lai, E; Takata, A; Tajiri, K; Toyoda, H; Tortora, R; Campani, C; Viola, M G; Piscaglia, F; Conti, F; Fulgenzi, C A M; Frassineti, G L; Rizzato, M D; Salani, F; Astara, G; Torimura, T; Atsukawa, M; Tada, T; Burgio, V; Rimini, M; Cascinu, S; Casadei-Gardini, A

Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey

胰腺导管腺癌合并生殖系BRCA1-2致病变异(gBRCA1-2pv)患者的化疗毒性和疗效:一项多中心调查

Orsi, G; Di Marco, M; Cavaliere, A; Niger, M; Bozzarelli, S; Giordano, G; Noventa, S; Rapposelli, I G; Garajova, I; Tortora, G; Rodriquenz, M G; Bittoni, A; Penzo, E; De Lorenzo, S; Peretti, U; Paratore, C; Bernardini, I; Mosconi, S; Spallanzani, A; Macchini, M; Tamburini, E; Bencardino, K; Giommoni, E; Scartozzi, M; Forti, L; Valente, M M; Militello, A M; Cascinu, S; Milella, M; Reni, M

Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort

生殖细胞BRCA1-2致病变异(gBRCA1-2pv)与胰腺癌:意大利患者队列的流行病学研究

Peretti, U; Cavaliere, A; Niger, M; Tortora, G; Di Marco, M C; Rodriquenz, M G; Centonze, F; Rapposelli, I G; Giordano, G; De Vita, F; Stuppia, L; Avallone, A; Ratti, M; Paratore, C; Forti, L G; Orsi, G; Valente, M M; Gaule, M; Macchini, M; Carrera, P; Calzavara, S; Simbolo, M; Melisi, D; De Braud, F; Salvatore, L; De Lorenzo, S; Chiarazzo, C; Falconi, M; Cascinu, S; Milella, M; Reni, M

Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation"

关于“循环癌症干细胞衍生的细胞外囊泡作为临床结果评估的新型生物标志物”的更正

Brocco, D; Lanuti, P; Simeone, P; Bologna, G; Pieragostino, D; Cufaro, M C; Graziano, V; Peri, M; Di Marino, P; De Tursi, M; Grassadonia, A; Rapposelli, I G; Pierdomenico, L; Ercolino, E; Ciccocioppo, F; Del Boccio, P; Marchisio, M; Natoli, C; Miscia, S; Tinari, N

Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation.

循环癌干细胞衍生的细胞外囊泡作为临床结果评估的新型生物标志物

Brocco D, Lanuti P, Simeone P, Bologna G, Pieragostino D, Cufaro M C, Graziano V, Peri M, Di Marino P, De Tursi M, Grassadonia A, Rapposelli I G, Pierdomenico L, Ercolino E, Ciccocioppo F, Del Boccio P, Marchisio M, Natoli C, Miscia S, Tinari N

Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer

双重靶向ErbB-2/ErbB-3可增强胰腺癌临床前模型中的抗肿瘤活性

Ghasemi, R; Rapposelli, I G; Capone, E; Rossi, C; Lattanzio, R; Piantelli, M; Sala, G; Iacobelli, S